These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 18227600)

  • 1. Evaluation of a modified double-disc synergy test for detection of extended spectrum beta-lactamases in AMPC beta-lactamase-producing proteus mirabilis.
    Khan MK; Thukral SS; Gaind R
    Indian J Med Microbiol; 2008; 26(1):58-61. PubMed ID: 18227600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of the cefepime-clavulanate ESBL Etest for detection of extended-spectrum beta-lactamases in AmpC co-producing bacteria.
    Mohanty S; Gaind R; Ranjan R; Deb M
    J Infect Dev Ctries; 2009 Nov; 4(1):24-9. PubMed ID: 20130375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancing Phenotypic Detection of ESBL in AmpC co-producers by using Cefepime and Tazobactam.
    Kaur J; Mahajan G; Chand K; Sheevani ; Chopra S
    J Clin Diagn Res; 2016 Jan; 10(1):DC05-8. PubMed ID: 26894064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AmpC β-lactamases in nosocomial isolates of Klebsiella pneumoniae from India.
    Gupta V; Kumarasamy K; Gulati N; Garg R; Krishnan P; Chander J
    Indian J Med Res; 2012 Aug; 136(2):237-41. PubMed ID: 22960890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotypic characteristics of clinical isolates of Klebsiella pneumoniae & evaluation of available phenotypic techniques for detection of extended spectrum beta-lactamases.
    Manchanda V; Singh NP; Goyal R; Kumar A; Thukral SS
    Indian J Med Res; 2005 Oct; 122(4):330-7. PubMed ID: 16394326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations.
    Luzzaro F; Perilli M; Amicosante G; Lombardi G; Belloni R; Zollo A; Bianchi C; Toniolo A
    Int J Antimicrob Agents; 2001 Feb; 17(2):131-5. PubMed ID: 11165117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) program.
    Wang JT; Chen PC; Chang SC; Shiau YR; Wang HY; Lai JF; Huang IW; Tan MC; Lauderdale TL;
    BMC Infect Dis; 2014 Sep; 14():486. PubMed ID: 25192738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of extended-spectrum β-lactamase, AmpC, and carbapenemase production in Proteus mirabilis.
    Datta P; Gupta V; Arora S; Garg S; Chander J
    Jpn J Infect Dis; 2014; 67(1):44-6. PubMed ID: 24451101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial activity of cefepime-tazobactam combination against extended spectrum beta-lactamase and/or AmpC beta-lactamase- producing gram-negative bacilli.
    Elawady BA; Mahmoud NR; Badawi HE; Badr AEE; Gohar NM
    BMC Infect Dis; 2024 Apr; 24(1):434. PubMed ID: 38654148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of boronic acid disk methods to detect the combined expression of plasmid-mediated AmpC beta-lactamases and extended-spectrum beta-lactamases in clinical isolates of Klebsiella spp., Salmonella spp., and Proteus mirabilis.
    Song W; Jeong SH; Kim JS; Kim HS; Shin DH; Roh KH; Lee KM
    Diagn Microbiol Infect Dis; 2007 Mar; 57(3):315-8. PubMed ID: 17174510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of clinical isolates of Klebsiella pneumoniae from 19 laboratories using the National Committee for Clinical Laboratory Standards extended-spectrum beta-lactamase detection methods.
    Steward CD; Rasheed JK; Hubert SK; Biddle JW; Raney PM; Anderson GJ; Williams PP; Brittain KL; Oliver A; McGowan JE; Tenover FC
    J Clin Microbiol; 2001 Aug; 39(8):2864-72. PubMed ID: 11474005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended spectrum AmpC and metallo-beta-lactamases in Serratia and Citrobacter spp. in a disc approximation assay.
    Rizvi M; Fatima N; Rashid M; Shukla I; Malik A; Usman A; Siddiqui S
    J Infect Dev Ctries; 2009 May; 3(4):285-94. PubMed ID: 19759492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended spectrum AmpC and metallo-beta-lactamases in Serratia and Citrobacter spp. in a disc approximation assay.
    Rizvi M; Fatima N; Rashid M; Shukla I; Malik A; Usman A; Siddiqui S
    J Infect Dev Ctries; 2009 Apr; 3(3):177-86. PubMed ID: 19759472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular epidemiology and antimicrobial susceptibility of AmpC- and/or extended-spectrum (ESBL) ß-lactamaseproducing Proteus spp. clinical isolates in Zenica-Doboj Canton, Bosnia and Herzegovina.
    Uzunović S; Ibrahimagić A; Hodžić D; Bedenić B
    Med Glas (Zenica); 2016 Aug; 13(2):103-12. PubMed ID: 27313108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China.
    Yang Q; Zhang H; Cheng J; Xu Z; Xu Y; Cao B; Kong H; Ni Y; Yu Y; Sun Z; Hu B; Huang W; Wang Y; Wu A; Feng X; Liao K; Shen D; Hu Z; Chu Y; Lu J; Su J; Gui B; Duan Q; Zhang S; Shao H
    Int J Antimicrob Agents; 2015 May; 45(5):485-90. PubMed ID: 25600890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-spectrum beta-lactamase-mediated resistance among bacterial isolates recovered from ocular infections.
    Jayahar Bharathi M; Ramakrishnan R; Ramesh S; Murugan N
    Ophthalmic Res; 2012; 47(1):52-6. PubMed ID: 21720185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI screening parameters for the detection of extended-spectrum β-lactamase production in clinical Enterobacteriaceae isolates.
    Polsfuss S; Bloemberg GV; Giger J; Meyer V; Hombach M
    J Antimicrob Chemother; 2012 Jan; 67(1):159-66. PubMed ID: 21972269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the NCCLS extended-spectrum beta-lactamase confirmation methods for Escherichia coli with isolates collected during Project ICARE.
    Tenover FC; Raney PM; Williams PP; Rasheed JK; Biddle JW; Oliver A; Fridkin SK; Jevitt L; McGowan JE;
    J Clin Microbiol; 2003 Jul; 41(7):3142-6. PubMed ID: 12843054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Clinical and Laboratory Standards Institute phenotypic confirmatory test to detect the presence of extended-spectrum β-lactamases from 4005 Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae and Proteus mirabilis isolates.
    Morrissey I; Bouchillon SK; Hackel M; Biedenbach DJ; Hawser S; Hoban D; Badal RE
    J Med Microbiol; 2014 Apr; 63(Pt 4):556-561. PubMed ID: 24478449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis.
    Tsai HY; Chen YH; Tang HJ; Huang CC; Liao CH; Chu FY; Chuang YC; Sheng WH; Ko WC; Hsueh PR
    Diagn Microbiol Infect Dis; 2014 Nov; 80(3):222-6. PubMed ID: 25139843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.